These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2753072)

  • 1. Pharmacokinetic and metabolic studies of high-dose busulphan in adults.
    Hassan M; Oberg G; Ehrsson H; Ehrnebo M; Wallin I; Smedmyr B; Tötterman T; Eksborg S; Simonsson B
    Eur J Clin Pharmacol; 1989; 36(5):525-30. PubMed ID: 2753072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy.
    Hassan M; Ehrsson H; Smedmyr B; Tötterman T; Wallin I; Oberg G; Simonsson B
    Bone Marrow Transplant; 1989 Jan; 4(1):113-4. PubMed ID: 2647175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
    Hassan M; Oberg G; Björkholm M; Wallin I; Lindgren M
    Cancer Chemother Pharmacol; 1993; 33(3):181-6. PubMed ID: 8269597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
    Schuler US; Renner UD; Kroschinsky F; Johne C; Jenke A; Naumann R; Bornhäuser M; Deeg HJ; Ehninger G
    Br J Haematol; 2001 Sep; 114(4):944-50. PubMed ID: 11564090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
    Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
    Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of liposomal busulphan in man.
    Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
    Bone Marrow Transplant; 2001 Mar; 27(5):479-85. PubMed ID: 11313681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.
    Hassan M; Oberg G; Bekassy AN; Aschan J; Ehrsson H; Ljungman P; Lönnerholm G; Smedmyr B; Taube A; Wallin I
    Cancer Chemother Pharmacol; 1991; 28(2):130-4. PubMed ID: 2060084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization.
    Effting C; de Moraes Arantes A; Queiroz Labre LV; Carneiro WJ; de Oliveira Neto JR; Bariani C; Rodrigues CR; Rodrigues AR; Cunha LC
    Ther Drug Monit; 2015 Feb; 37(1):66-70. PubMed ID: 25588069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.
    Hassan M; Ehrsson H; Wallin I; Eksborg S
    Eur J Drug Metab Pharmacokinet; 1988; 13(4):301-5. PubMed ID: 3243326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
    Poonkuzhali B; Srivastava A; Quernin MH; Dennison D; Aigrain EJ; Kanagasabapathy AS; Krishnamoorthy R; Chandy M
    Bone Marrow Transplant; 1999 Jul; 24(1):5-11. PubMed ID: 10435727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of high-dose busulfan in children.
    Vassal G; Gouyette A; Hartmann O; Pico JL; Lemerle J
    Cancer Chemother Pharmacol; 1989; 24(6):386-90. PubMed ID: 2791192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high dose busulphan on leukaemic progenitor cells in chronic myeloid leukaemia.
    Morstyn G; Sullivan J; Fairhead S; Cowling D; Hurley T
    Aust N Z J Med; 1981 Dec; 11(6):609-14. PubMed ID: 6949537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.
    Faraci M; Tinelli C; Lanino E; Giardino S; Leoni M; Ferretti M; Castagnola E; Broglia M; De Silvestri A; Di Martino D; Bartoli A
    Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):173-181. PubMed ID: 28801891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.
    Boland I; Vassal G; Morizet J; Terrier-Lacombe MJ; Valteau-Couanet D; Kalifa C; Hartmann O; Gouyette A
    Br J Cancer; 1999 Feb; 79(5-6):787-92. PubMed ID: 10070870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan kinetics.
    Ehrsson H; Hassan M; Ehrnebo M; Beran M
    Clin Pharmacol Ther; 1983 Jul; 34(1):86-9. PubMed ID: 6574831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
    Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine.
    El-Serafi I; Terelius Y; Twelkmeyer B; Hagbjörk AL; Hassan Z; Hassan M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():98-105. PubMed ID: 23286981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.